Muneel Abbas, MD
Family Medicine · Williamson, WVNPI 1740404375
Payments from drug & device makers
Across 243 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$677
- AbbVie$549
- Novo Nordisk$468
- Bayer$287
- Abbott$186
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$170
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $677 |
| AbbVie(2 entities) | 38 | $549 |
| Novo Nordisk | 29 | $468 |
| Bayer | 20 | $287 |
| Abbott | 12 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $170 |
| Pfizer | 10 | $136 |
| Boehringer Ingelheim | 9 | $131 |
| Lilly USA, LLC | 9 | $129 |
| Sanofi-aventis U.S. LLC | 10 | $126 |
| Insmed, Inc. | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $105 |
| Biohaven Pharmaceuticals, Inc. | 5 | $83 |
| Amgen | 5 | $82 |
| Novartis | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Amarin Pharma, Inc. | 5 | $75 |
| GSK | 5 | $71 |
| Dexcom, Inc. | 4 | $66 |
| Verona Pharma, Inc. | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 4 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Johnson & Johnson | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$3,970 in reported general payments places this provider in the 85th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $176,782 |
| OzempicSemaglutide | 133 | $173,600 |
| MounjaroTirzepatide | 60 | $97,277 |
| FarxigaDapagliflozin Propanediol | 101 | $94,651 |
| EnbrelEtanercept | 13 | $92,180 |
| XifaxanRifaximin | 29 | $90,463 |
| JardianceEmpagliflozin | 92 | $87,939 |
| XareltoRivaroxaban | 87 | $71,009 |
| EntrestoSacubitril/Valsartan | 92 | $61,515 |
| JanuviaSitagliptin Phosphate | 74 | $60,749 |
| Invega SustennaPaliperidone Palmitate | 11 | $40,317 |
| TradjentaLinagliptin | 41 | $36,577 |
| MultaqDronedarone Hcl | 40 | $36,538 |
| LinzessLinaclotide | 40 | $36,436 |
| KerendiaFinerenone | 41 | $34,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $176,782243 claims |
| Novo NordiskOzempic | $468 | $173,600133 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $677 | $150,632191 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $131 | $138,263150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $129 | $129,56482 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $20 | $111,32798 claims |
| AmgenEnbrel | $82 | $92,18013 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $170 | $90,46329 claims |
| NovartisEntresto | $78 | $61,51592 claims |
| MerckJanuvia | $12 | $60,74974 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta | $71 | $58,96593 claims |
| Sanofi-aventis U.S. LLCMultaq, Lantus | $126 | $45,653107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Williamson
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.